Misty Abt

Highly-motivated employee with desire to take on new challenges. Strong work ethic, adaptability, and exceptional interpersonal skills. Adept at working effectively unsupervised and quickly mastering new skills.

Talented in multiple areas in the medical field with 5 years experience in Ophthalmic Tech with 3 years experience in study visions and 17 years experience as a CNA. Outstanding customer service to patients/guests, customers and staff.

AMD Studies 

- 2022 - Present - A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients with Neovascular (Wet) Age related Macular Degeneration (nAMD) (LUNA). Adverum Biotechnologies, Inc. (ADVM-022-11), 

- 2022 - Present - A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). Alexion Pharmaceuticals, Inc. (ALXN2040-GA-201), 

- 2022 - Present - A Global, Phase III, Double Blind, Randomized Controlled Study to Compare the Efficacy, Safety & Immunogenicity of LUBT010 with Lucentis in Patients with Neovascular AgeRelated Macular Degeneration (Lupin). Lupin Limited (Biotechnology Division) (LRP/LUBT010/2016/008), 

- 2021 - Present - F. Hoffman-La Roche Ltd, Genentech, Inc., Avonelle-X (GR42691): A Multicenter, Openlabel Extension Study to Evaluate the Long-term Safety and Tolerability of Faricimab in Patients with Neovascular Age-Related Macular Degeneration., 

- 2021 - Present - Apellis Pharmaceuticals, Gale (APL2-305): A Phase 3, Open-label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration., 

- 2021 - Present - RegenXBio, Atmosphere (RGX-314-2104): A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD., 

- 2021 - Present - Opthea, Coast (OPT-302-1005): Principal Investigator. "A -Phase 3, Multicentre, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)., 

- 2021 - August 2023 - Kodiak Sciences Inc., Daylight (KS301P107): A Prospective, Randomized, Doublemasked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)., 

- 2021 - 2022 - NGM Biopharmaceuticals, Inc., Catalina (NGM621-GA-201): A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration., 

- 2021 - 2022 - Gemini Therapeutics, Inc., Regatta (GEM-CL-10302): A Multicenter, Open-label, Multiple Dose Study in Patients with Geographic Atrophy Secondary to Dry Age-related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103., 

- 2021 - Present - Bayer AG/Regeneron Pharmaceuticals Inc., Pulsar (20968): Randomized, DoubleMasked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration., 

- 2021 - Present - Iveric Bio, ISEE2008: A Phase 3Multicenter, Randomized, Double-Masked, ShamControlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) In Patients with Geographic Atrophy Secondary to AgeRelated Macular Degeneration., 

- 2021 - Present - Amgen Inc., 20170542: A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea) in Subjects with Neovascular Age-related Macular Degeneration., 

- 2021 - 2022 - Kodiak Sciences Inc., Dazzle (KSI-CL-102): A Phase 2, Prospective, Randomized, Doublemasked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Agerelated Macular Degeneration.,

DME Studies, 

- 2022 - Present - A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Diabetic Macular Edema." F. Hoffman-La Roche Ltd (BP43445), 

- 2022 - Present - A Phase IIIB/IV, Multicenter, Open-Label, Single-Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naïve, Underrepresented Patients with Diabetic Macular Edema. Genentech, Inc. (ML43435), 

- 2022 - January 2023 - A Phase 2/3 Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema." Oculis SA. (DX219), 

- 2021 - August 2023 - Kodiak Sciences Inc., Gleam (KS301P104): A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)., 

- 2021 - Present - Regeneron Pharmaceuticals, Inc., Photon (VGFT3-HD-DME-1934): A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema.,

RVO Studies, 

- 2021 - July 2023 - F. Hoffman-La Roche Ltd, Genentech, Inc., Comino (GR41986): A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab In Patients with Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion., 

- 2021 - July 2023 - F. Hoffman-La Roche Ltd, Genentech, Inc., Balaton (GR41984): A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion., 

- 2021 - January 2023 - Kodiak Sciences Inc., Beacon (KS301P103): A Prospective, Randomized, Doublemasked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO).,

Other Studies, 

- 2021 - 2022 - Ocuphire Pharma, Inc., OPI-APXD-201: A Randomized, Placebo-Controlled, DoubleMasked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy or Mild Proliferative Diabetic Retinopathy.